Original Research Article

Ki67 and P53 expression in breast cancer and their correlation with clinicopathological parameters

Sukanya Gogoi1,*, Bandita Das1, Mondita Borgohain1, Gayatri Gogoi1, Jayanta Das2

1 Dept. of Pathology, Assam Medical College, Dibrugarh, Assam, India
2 Excel Care Hospital, Guwahati, Assam, India

ARTICLE INFO

Article history:
Received 09-08-2021
Accepted 02-09-2021
Available online 23-11-2021

Keywords:
Breast cancer
Clinicopathological parameters
Ki 67
P53

ABSTRACT

Introduction: Breast carcinoma is the most common malignancy in females and is a leading cause of death. Treatment depends upon various pathological and prognostic markers like lymph node status, size, type and grade of the tumour which influences the outcome of breast cancer. Markers like Ki-67 and p53 have been studied extensively and their roles in breast cancer are yet to be established. We evaluated the expression of Ki67 and P53 in breast cancer and their association with other clinicopathological factors was studied.

Materials and Methods: Ki67 and P53 expression was assessed in 60 breast cancer cases admitted to our hospital over a period of one year. Association with other prognostic parameters was evaluated. Statistical analysis was done by Chi square test and a p value of <0.05 was taken as significant.

Results: 43.33% cases had low proliferative Ki-67 score whereas 56.67% of the cases were highly proliferative. p53 expression was seen in 41.66% cases. Ki-67 and p53 expression were not significantly related to age, menopausal status, and tumour size whereas a significant correlation was seen with positive axillary lymph node status, high histological grade, negative hormone receptor status (ER, PR) and positive HER2/neu expression. Significant association was seen between Ki-67 and p53 expression.

Conclusion: Ki67 and P53 may be considered as a valuable biomarker in breast cancer patients which can help in planning treatment strategies.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Breast carcinoma is the most common malignancy in females worldwide and is a leading cause of death in women.1 It now represents one in four of all cancers in women.2 The treatment of breast cancer depends on various pathological and clinical prognostic markers. These include lymph node status, size, type and grade of the tumour which influence the outcome. Hormone receptor status [including the estrogen receptor (ER) and progesterone receptor (PR)] and human epidermal growth factor receptor 2 (Her2/neu) expression are universally used as biomarkers for breast cancer which are analysed using Immunohistochemistry (IHC).3

These biomarkers are used as a prognostic indicator as well as a predictor of response to hormonal and chemotherapy and helps in deciding the adjuvant therapy of breast cancer. Apart from ER, PR and HER2/neu, there are various other markers which have been widely studied in order to assess their relationship with the clinicopathological parameters of breast cancer and also to assess their role in deciding the treatment and in influencing the outcome. Two such markers are Ki-67 and p53 which have been studied extensively and whose roles in breast cancer are yet to be established.4

https://doi.org/10.18231/j.ijpo.2021.099
2394-6784/© 2021 Innovative Publication, All rights reserved. 478
Ki-67 is a labile, nonhistone nuclear protein that is tightly linked to the cell cycle and is expressed in all continuously cycling cells of mid-G1, S, and G2 phase and in mitosis, but not in quiescent or resting cells in the G0 and early G1 phase. As this protein is present in all proliferating cells, it may serve as a marker to evaluate the growth fraction of a given cell population. Even though there are several published papers evaluating the prognostic role of Ki-67 in breast cancer, it is still not considered as an established marker to be used in clinical practice. Therefore, understanding the association of Ki-67 with pathological characteristics (including histological grade, tumor size and lymph node metastasis) and immunohistochemical indexes including ER, PR and HER2 status is important for clinical evaluations and guiding treatment strategies.

The p53 gene is a tumor suppressor gene that is located on the short arm of chromosome 17 (17p31.1). Because a mutated p53 gene produces proteins that are not degraded as quickly as the wild type protein, p53 protein accumulate and can be detected by immunohistochemistry. Through its target protein it helps in DNA repair, senescence, aging, differentiation, cell adhesion, cell mobility, membrane functions, metabolism and autophagy.

Even though p53 expression is associated with poor outcome in breast cancer, its vitality as a prognostic marker has been controversial and has not been recommended for routine clinical use. Thus the study of this marker and its impact on breast cancer prognosis is important for its potential clinical utility which might contribute to further advances in deciding treatment strategies.

The aim of this study is to evaluate the expression of Ki-67 and p53 in breast cancer and to correlate these markers with various clinicopathological parameters.

2. Materials and Methods

The study was undertaken at a tertiary care hospital in Dibrugarh. A total of 60 invasive breast cancer cases which were diagnosed over a period of one year between June 2016-May 2017 were included in this study. Detailed history, clinical data and laboratory investigations were collected for each cases. Haematoxylin and eosin stained sections were examined and tumours were categorized according to WHO Classification of tumours. Each case was histologically graded according to Modified Bloom Richardson System. Clinicopathological parameters including age at diagnosis, tumour size, histological type, tumour grade and lymph node status were considered.

2.1. Immunohistochemical (IHC) staining

3-5 mm sections of the representative area of the tumour from the paraffin embedded blocks were taken for immunohistochemical studies using a rotary microtome (LEICA RM 215RT). Slides were deparaffinized in 2 changes of xylene and then rehydrated through a series of graded alcohol (absolute, 70 & 50%). An antigen retrieval system was used for optimal retrieval of epitopes. Blocking of endogenous peroxidase activity was done by adding peroxidase blocking agent. Sections were incubated with relevant primary antibodies (ready to use with biogenes detection system) in a humid chamber which was followed by incubation with secondary antibody (polymer Horseradish peroxidase) and freshly prepared Diaminobenzidine chromogen. The slides were then counterstained with hematoxylin.

2.2. Ki67 immunohistochemical scoring

The percentage of Ki-67-positive cells was determined in 10 high power fields by counting no less than 1,000 cells in different areas of each section. Only tumor cells with nuclear positivity were considered for the score.

2.3. Ki-67 labelling index (LI)

The Ki-67 labelling index is defined as the percentage of positively stained tumor cells among the total number of malignant cells assessed.

\[
\text{Ki-67 LI} = \frac{\text{No of cells showing positive nuclear staining}}{\text{Total number of cells}} \times 100
\]

Grading of Ki-67 expression:

- Low proliferative: < 20% Ki-67-positive cells
- High proliferative: ≥ 20% Ki-67-positive cells

Grading of P53 expression:

- Negative: <10% of cancer cells (focal staining)
- 1+: 10 to 49% of cancer cells (heterogeneous or focal staining)
- 2+: ≥ 50% of cancer cells (homogeneous and diffuse staining)

Statistical analysis was done by using Chi square test. A p value of <0.05 was considered as significant.

3. Result

The breast cancer cases were assessed for various clinicopathological parameters (Table 1). Out of 60 cases, majority (46 cases) were Invasive Ductal Carcinoma, Not otherwise specified (NOS). The mean age at diagnosis was 45.72 years (range 28-70 years). Four cases (6.67%) had tumour size <2cm, 39 cases (65%) had size between 2-5cm and 17 cases (28.33%) had size >5cm. 12 patients (20%), 34 (56.6%) and 14 (23.3%) had histological grades I, II and III respectively. Lymph node metastasis was seen in 33 cases (55%) and was negative in 27 cases (45%). ER, PR and Her 2 expression
Table 1: Clinico-pathological parameters and immunoprofile in 60 breast cancer cases

| Tumour Variables              | No. of cases | Percentage(%) |
|------------------------------|--------------|---------------|
| Age                          |              |               |
| <50 years                    | 37           | 62            |
| ≥ 50 years                   | 23           | 38            |
| Tumour size                  |              |               |
| <2cm                         | 4            | 7             |
| 2-5cm                        | 39           | 65            |
| >5cm                         | 17           | 28            |
| Lymph Node Status            |              |               |
| Negative                     | 27           | 45            |
| 1-4                          | 22           | 37            |
| >4                           | 11           | 18            |
| Histological Grade           |              |               |
| I                            | 12           | 20            |
| II                           | 34           | 57            |
| III                          | 14           | 23            |
| ER Status                    |              |               |
| Positive                     | 32           | 53            |
| Negative                     | 28           | 47            |
| PR Status                    |              |               |
| Positive                     | 28           | 47            |
| Negative                     | 32           | 53            |
| Her 2                        |              |               |
| Positive                     | 13           | 22            |
| Negative                     | 47           | 78            |
| Ki-67 LI                     |              |               |
| <20%                         | 26           | 43            |
| ≥ 20%                        | 34           | 57            |
| P53 Expression               |              |               |
| Negative                     | 35           | 58            |
| 1+                           | 16           | 27            |
| 2+                           | 9            | 15            |

was seen in 32(53.3%), 28 (46.6%) and 13 (21.6%) breast cancer cases respectively.

3.1. Ki67 and P53 expression in breast cancer and correlation with clinico-pathological parameters

Out of 60 breast cancer cases, 34 cases (56.6%) had high Ki67 proliferative index (Ki67 LI >20%) whereas 26 cases (43.33%) had low Ki67 proliferative activity (Ki67 LI<20%). P53 expression was seen in 25 cases (41.66%) and was negative in 35 cases (58.33%). The correlation of Ki67 and P53 expression with other parameters of breast cancer has been shown in Table 2 and Table 3 respectively. In the present study, it was seen that the Ki-67 and p53 expression was significantly related to the positive axillary lymph node status, high histological grade, negative hormone receptor status (ER, PR) and positive HER2/neu expression (p<0.05).

3.2. Correlation of Ki67 with P53 expression in breast cancer

In the present study, P53 expression was seen to be higher in tumours that were highly proliferative. Out of 25 cancers which were positive for P53 expression, 23 cases (92%) had high Ki67 proliferative index. Whereas, out of 35 cancers which were negative for P53 expression, 24 cases (68.57%) had low Ki LI of <20% (Table 4). Thus a statistically significant correlation was found between Ki-67 and p53 expression. (p value<0.05).

4. Discussion

The present study was carried out in a tertiary care hospital, Dibrugarh, from June 2016 to May 2017 over a period of one year. A total of 60 breast cancers were studied during this period.

Clinical history and routine investigations available with the patients were recorded. Histopathological
Table 2: Ki-67 expression in breast cancer and correlation with clinico-pathological parameters

| Tumour Variables          | Ki67 LI <20% | Ki67 LI ≥ 20% | P value |
|---------------------------|--------------|---------------|---------|
|                           | No. | %  | No. | %  |        |
| Age                       |     |    |     |    |        |
| <50 years                 | 15  | 41 | 22  | 59 | 0.57   |
| ≥ 50 years                | 11  | 48 | 12  | 52 |        |
| Tumour size               |     |    |     |    |        |
| <2 cm                     | 2   | 50 | 2   | 50 | 0.94   |
| 2-5 cm                    | 17  | 44 | 22  | 56 |        |
| >5 cm                     | 7   | 41 | 10  | 59 |        |
| Lymph Node Status         |     |    |     |    |        |
| Negative                  | 20  | 74 | 7   | 26 |        |
| 1-4                       | 5   | 23 | 17  | 77 | 0.006  |
| >4                        | 1   | 9  | 10  | 91 |        |
| Histological Grade        |     |    |     |    |        |
| I                         | 11  | 92 | 1   | 8  | 0.0002 |
| II                        | 13  | 38 | 21  | 62 |        |
| III                       | 2   | 14 | 12  | 86 |        |
| ER Status                 |     |    |     |    |        |
| Positive                  | 23  | 72 | 9   | 28 | 0.001  |
| Negative                  | 3   | 11 | 25  | 89 |        |
| PR Status                 |     |    |     |    |        |
| Positive                  | 21  | 75 | 7   | 25 | 0.002  |
| Negative                  | 5   | 16 | 27  | 84 |        |
| Her 2                     |     |    |     |    |        |
| Positive                  | 2   | 15 | 11  | 85 | 0.03   |
| Negative                  | 24  | 51 | 23  | 49 |        |

Table 3: P53 expression in breast cancer and correlation with clinico-pathological parameters

| Tumour Variables          | P53 Negative | P53 Positive | P value |
|---------------------------|--------------|--------------|---------|
|                           | No. | %  | No. | %  |       |
| Age                       |     |    |     |    |        |
| <50 years                 | 22  | 59 | 15  | 41 | 0.822 |
| ≥ 50 years                | 13  | 57 | 16  | 41 |        |
| Tumour size               |     |    |     |    |        |
| <2 cm                     | 2   | 50 | 2   | 50 | 0.94  |
| 2-5 cm                    | 23  | 59 | 16  | 41 |        |
| >5 cm                     | 10  | 59 | 7   | 41 |        |
| Lymph Node Status         |     |    |     |    |        |
| Negative                  | 25  | 93 | 2   | 7  | 0.001 |
| 1-4                       | 9   | 41 | 13  | 59 |        |
| >4                        | 1   | 9  | 10  | 91 |        |
| Histological Grade        |     |    |     |    |        |
| I                         | 9   | 75 | 3   | 25 | 0.006 |
| II                        | 24  | 71 | 10  | 29 |        |
| III                       | 2   | 14 | 12  | 86 |        |
| ER Status                 |     |    |     |    |        |
| Positive                  | 25  | 78 | 7   | 22 | 0.003 |
| Negative                  | 10  | 36 | 18  | 64 |        |
| PR Status                 |     |    |     |    |        |
| Positive                  | 23  | 82 | 5   | 18 | 0.004 |
| Negative                  | 12  | 38 | 20  | 63 |        |
| Her 2                     |     |    |     |    |        |
| Positive                  | 3   | 23 | 10  | 77 | 0.008 |
| Negative                  | 30  | 64 | 17  | 36 |        |

Table 4: Correlation between P53 expression and Ki-67 LI in breast cancer

| P53 Expression | Ki-67 LI<20% | Ki-67 LI≥ 20% | P value |
|----------------|--------------|---------------|---------|
|                | No. | %  | No. | %  |       |
| Negative       | 24  | 69 | 11  | 31 | 0.001 |
| Positive       | 2   | 8  | 23  | 92 |       |

Labelling Index (LI)
examination of the tissue specimens received was done. Immunohistochemistry was done with Ki-67 and p53 to look into the expression profile in neoplastic lesions and its correlation with clinicopathological parameters in breast cancers was analysed. The results obtained were compared with those of other similar studies done by previous workers.

In the present study, 56.67% of the breast cancers were highly proliferative while 43.33% cases had low Ki 67 proliferative index which is similar to the studies done by Madani SH et al.,12 Wang XZ et al.,10 Payandeh et al.13 and Hassan I et al.14 Also the mean Ki LI was found to be 28 (±20.27) with a range of 2–80%. According to various literatures, the cut off for Ki-67 LI has varied from 5 to 30%. Since there are no fixed standards for the Ki-67 cut-off value and also because of the use of different antibodies, there are variations in the findings of Ki-67 LI scores among the various studies.

In our study a statistically significant correlation was found between Ki-67 and lymph node status. This is similar to the findings of Kilickap et al.,15 Sharath et al.3 and Nishimura et al.16 who also found that higher Ki-67 proliferative index was seen in tumours having more than 4 lymph nodes positivity. A statistically significant correlation was found between Ki-67 proliferation and histological grade. Higher Ki-67 LI was seen in grade III tumours. This is similar to the studies of Kilickap et al,15 Sharath et al1 and Hassan et al.14

Among the immunohistochemical markers studied, a statistically significant negative correlation was found between Ki67 and ER/PR status and a positive correlation was found with Her2/neu. This is similar to the findings of Madani et al,12 Kilickap et al,15 Nishimura et al,16 Inwald EC et al9 and Haroon S et al.4 Higher Ki-67 LI was seen in tumours which were negative for ER and PR. Also, it was seen that higher Ki-67 proliferation was seen in tumours showing higher expression of Her2/neu.

In the present study, higher Ki-67 LI was seen in tumours with positive lymph node involvement, higher histological grade, negative ER and PR status and with positive HER2/neu expression all of which are poor prognostic factors in breast cancer.

In the present study, 58.33% of the cases were negative for p53 expression. 26.67% of the cases showed p53 expression in 10 to 50% of the cancer cells, i.e, 1+ and 15% cases showed p53 positivity in more than 50% of the cancer cells, i.e, 2+. Thus p53 expression was seen in 41.66% of the cases. This is comparable with the work of Madani et al.,12 Wang XZ et al.,10 Payandeh et al.13and Kikuchi et al.11 There is a wide variation in the expression of p53 amongst different authors. These differences may be due to heterogenous group of population, different methods for assaying p53, or different cut offs to designate high or low p53 expression. In most of the studies, a cut off of 10% has
been considered.

In the present study, a significant positive correlation was found between p53 expression and lymph node status. This is similar to the studies of Kikuchi et al., Payandeh et al., Al-hamadami HA et al. and Abdollahi et al. where the expression of p53 increased with increasing number of lymph nodes involved.

A positive significant association was found with histological grade. Higher proportion of p53 positivity was seen in grade III tumours. This is similar to the findings of Kikuchi et al., Payandeh et al., Al-hamadawi HA et al. and Yamashita et al.

A significant inverse correlation was found with ER and PR status and a significant positive correlation was found with Her2/neu status. Higher expression of p53 was seen in tumours which were negative for ER and PR. Higher expression of p53 was seen in Her2/neu positive tumours. This is similar to the studies of Madani et al., Payandeh et al., Abdollahi et al. and Yamashita et al.

In the present study, higher p53 expression was seen in tumours with positive lymph node involvement, higher histological grade, negative ER and PR status and with positive HER2/neu expression all of which are linked to poor outcome in breast cancer.

In the present study, a positive significant correlation was seen between Ki67 and p53 expression. Thus Ki-67 expression was more in tumours with higher expression of p53. This is similar to the studies of Madani et al., Nishimura et al., Kikuchi et al., Payandeh et al. and Yamashita et al.

5. Conclusion

Although prognostic and predictive values of Ki-67 and p53 are well established, the clinical utilities of these markers are more useful in the combination with other prognostic markers especially hormone receptor status and HER2/neu expression. In the present study, it was found that both high Ki-67 index and p53 expression was significantly associated with positive lymph node status, high histological grade, ER, PR negativity and positive HER2/neu expression all of which are poor prognostic factors. Immunohistochemical determination of the Ki-67 proliferation index should be performed in cases of breast cancer, to obtain clinically useful information on tumour aggressiveness as reflected in their proliferative rate. Ki-67 can be used as an independent predictive and prognostic marker in managing breast cancer patients and as a predictor of response to hormonal and chemotherapy. Determination of the p53 status may be used as a biological marker to identify those patients who would benefit from more aggressive treatments. Easy availability in all laboratories and better standardization are required for their routine use. However, a much larger study needs to be done over a longer period of time with inter laboratory standardization to truly determine the value of these biomarkers as a diagnostic and prognostic tool in breast cancer.

6. Abbreviation

IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma.

7. Source of Funding

None.

8. Conflict of Interest

The authors declare no conflict of interest.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward EFD. Global cancer statistics. Cancer J Clin. 2011;61:69–90.
2. Sharmar M, Sharma KS, Sarma A, Ahmed S, Kataka AC, Saxena R. Triple Negative Breast Cancer in People of North East India: Critical Insights Gained at a Regional Cancer Centre. Asian Pac J Cancer Prev. 2014;15:4507–11.
3. Shk K, Shilpa K, Geeta S. Study of Ki-67 expression in carcinoma breast. Int J Appl Res. 2017;3:98–100.
4. Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B. Ki-67 index in breast cancer: Correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev. 2013;14:4353–8.
5. Park D, Käresen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their auxillary lymph node metastases: Clinical implications. Vircarchs Arch. 2007;451:11–8.
6. Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu Y. Associations and indications of Ki-67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncol Lett. 2015;10:1741–8.
7. Sana M, Irshad S. P53 As a Biomarker of Breast Cancer. Res Cancer Tumor. 2012;1:5-8.
8. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y. P53 Expression in Tumor-Stromal Fibroblasts Forming and Not Forming Fibrotic Foci in Invasive Ductal Carcinoma of the Breast. Mod Pathol. 2010;23:662–72.
9. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539–52.
10. Wang XZ, Liu Q, Sun JJ, Zuo WS, Hu DW, Ma SG. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res. 2015;14:4282–90.
11. Kikuchi S, Nishimura R, Osako T, Okumura Y, Nishiyama Y, Kikuchi et al. Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer. Anticancer Res. 2013;33:3891–8.
12. Madani SH, Payandeh M, Sadeghi M, Mattanied H, Sadeghi E. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian J Med Paediatr Oncol. 2016;37:95–9.
13. Payandeh M, Sadeghi M, Sadeghi E, Madani SH. Expression of p53 breast cancer in Kurdish women in the west of Iran: A reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev. 2016;17:1261–4.
14. Hassan I, Tarcisia T, Agnastina A, Cornelis A, Nasar IM. Ki-67 marker useful for classification of malignant invasive ductal breast cancer. Univ Med. 2015;32:179–86.
15. Kilicak S, Kaya Y, Yucel B, Tuncer E, Akgul N, Elagoz S. Higher Ki-67 Expression is Associated With Unfavorable Prognostic Factors
and Shorter Survival in Breast Cancer. *Asian Pac J Cancer Prev.* 2014;15:1381–5.

16. Nishimura R, Osako T, Okumura Y, Hayashi M, Totoyoozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. *Exp Ther Med.* 2010;1:747–54.

17. Al-hamadawi HA, Al-Kashwan2 TA, Al-Janabi AA, Al-bideri AW, Allebban ZS, Jaber AH, et al. Interaction between Altered P53 and PTEN Inactivation has a biological predictive implication in assessment of aggressive breast cancer. *Int J Curr Microbiol App Sci.* 2015;4:910–22.

18. Abdollahi A, Sheikhhbahaei S, Safinejad S, Jahanzad I. Correlation of ER, PR, HER-2 and P53 Immunoreactions with Clinico-Pathological Features in Breast Cancer. *Iran J Pathol.* 2013;8:147–52.

19. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Introduction Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. *Breast Cancer Res.* 2004;6:24–30.

**Author biography**

**Sukanya Gogoi,** Demonstrator [https://orcid.org/0000-0003-2175-5042](https://orcid.org/0000-0003-2175-5042)

**Bandita Das,** Associate Professor

**Mondita Borgohain,** Professor and HOD

**Gayatri Gogoi,** Assistant Professor

**Jayanta Das,** Consultant Pathologist

**Cite this article:** Gogoi S, Das B, Borgohain M, Gogoi G, Das J. Ki67 and P53 expression in breast cancer and their correlation with clinicopathological parameters. *Indian J Pathol Oncol* 2021;8(4):478-484.